Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...

Intellia also separately announced positive topline data today from the Phase 3 HAELO clinical trial of lonvo-z in HAE. The trial met its primary and all key secondary endpoints, demonstrating that a ...

Intellia Therapeutics reported that its in vivo CRISPR therapy, lonvo-z, met all primary and secondary endpoints in a Phase 3 trial for hereditary angioedema, with 62% of treated patients attack-free ...

Intellia Therapeutics’ in vivo CRISPR gene therapy, lonvo-z, significantly reduced hereditary angioedema attacks in a Phase III trial, meeting its primary endpoint. Patients receiving the one-time ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat ...

CRISPR gene editing machinery holds the potential to transform the treatment of numerous diseases, but it requires effective delivery systems to get into tissues and ...

CRISPR gene editing has revolutionized the field of molecular biology, offering precise, efficient, and versatile tools for genome modification. The technology has rapidly evolved beyond the original ...